When was AMPEL founded?

AMPEL was founded in 2013 and raised its 1st funding round 8 years after it was founded.

Where is AMPEL located?

AMPEL is headquartered in Charlottesville, United States.

Who is the current CEO of AMPEL?

Peter Lipsky of AMPEL. They have also founded 1 company.

How many employees does AMPEL have?

As of May 31, 2026, the latest employee count at AMPEL is 14.

Is AMPEL a funded company?

AMPEL is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Jan 29, 2021.

When was the latest funding round of AMPEL?

AMPEL's latest funding was a $***** Conventional Debt round on Dec 13, 2022, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.35B in funding in 2026 to date.

Where does AMPEL rank among its competitors?

AMPEL ranks 130th amongst 753 active competitors, of which 135 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was SeqOne, which secured $22.7M in May, 2025.

Who are the top competitors of AMPEL?

AMPEL's top competitors include Benchling, Helix and Deep Genomics. Among them, SeqOne secured the most recent funding round in May, 2025.

AMPEL - 2026 Company Profile, Team, Funding & Competitors

AMPEL is a funded company based in Charlottesville (United States), founded in 2013 by Amrie Grammer and Peter Lipsky. It operates as a Provider of bioinformatics platform for drug development. AMPEL has raised an undisclosed amount in funding. The company has 753 active competitors, including 135 funded and 56 that have exited. Its top competitors include companies like Benchling, Helix and Deep Genomics.

Company Details

Provider of a bioinformatics platform for drug development. It offers clinicians and biomedical companies with bioinformatics data and helps in developing personalized drugs.

Website: ampelbiosolutions.com
Social
Email ID: *****@ampel.org
Phone Number: +1 **********

Key Metrics

Founded Year

2013

Location

Charlottesville, United States

Stage

Funding Raised

Latest Funding Round

Conventional Debt, Dec 13, 2022, $*****

Investors

Coddle Creek Capital

Ranked

130^th among 753 active competitors

Employee Count

14 as on May 31, 2026

Similar Companies

Benchling & 992 more

View AMPEL's full profile

AMPEL has raised funding over 4 rounds. Its first funding round was on Jan 29, 2021. AMPEL has 1 institutional investor.

Here is the list of recent funding rounds of AMPEL:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 13, 2022	5276517	Conventional Debt	2068127	5901637	3295277	6649299
Jun 15, 2021	8122027	Conventional Debt	5663555	2465355	6932773	3092089
Feb 10, 2021	6089957	Conventional Debt	5796713	5895281	6041909	7030760

Access funding benchmarks and valuations. Sign up today!

View details of AMPEL's funding rounds and investors

The founders of AMPEL are Amrie Grammer and Peter Lipsky. Peter Lipsky is the CEO of AMPEL.

Here are the details of AMPEL's key team members:

Amrie Grammer: Founder of AMPEL.
Contact Info: 1 email address
Peter Lipsky: Co-Founder & CEO & Chief Medical Officer of AMPEL.
Contact Info: 1 email address

View details of AMPEL's Founder profiles and Board Members

AMPEL's employee count trend

AMPEL has 14 employees as of May 26. Here is AMPEL's employee count trend over the years:

Uncover AMPEL's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AMPEL include Benchling, Helix and Deep Genomics. Here is the list of Top 10 competitors of AMPEL, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Menlo Ventures & 28 others	73/100
2nd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
3rd	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	63/100
4th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, Nextech Invest & 10 others	62/100
5th	Congenica 2013, Cambridge (United Kingdom), Acquired	Developer of software for clinical genomic interpretation and variant analysis	$81.9M	IDO Investments, Tencent & 39 others	62/100
6th	Latch 2021, San Francisco (United States), Series A	Provider of a web-based platform for genomic bioinformatics	$33M	Lux Capital, Coatue & 7 others	58/100
7th	BC Platforms 1997, Zurich (Switzerland), Series D	Provider of a platforms for genomic data analysis and management	$47.1M	Jolt Capital, Debiopharm & 6 others	58/100
8th	SeqOne 2017, Montpellier (France), Series A	Provider of bioinformatics tools for the analysis of genome sequencing data	$48.8M	Elaia, Omnes Capital & 7 others	57/100
9th	BostonGene 2015, Waltham (United States), Series B	Developer of cloud-based information and analytics platform to treat cancer	$200M	NEC, Japan Industrial Partners & 1 others	57/100
10th	Genedata 1997, Basel (Switzerland), Acquired	Software solutions for drug discovery, industrial biotechnology, and life science research	-	Novartis Venture Fund, Alta Partners & 1 others	56/100
130th	AMPEL 2013, Charlottesville (United States), Funding Raised	Provider of bioinformatics platform for drug development	-	Coddle Creek Capital	35/100